Epamed s.r.o.
- Address
- lock Available on a paid plan
Psychiatry and Psychology in Schizophrenia
At Epamed s.r.o. in Košice, research in psychiatry focuses on schizophrenia and related symptoms such as negative symptoms and cognitive impairment. These studies are designed to evaluate new treatment options and monitor longer-term safety for people living with this complex mental health condition.
- Testing new approaches for negative symptoms in schizophrenia
- Collecting additional safety data in patients with schizophrenia-related cognitive impairment
- Exploring treatment effectiveness and tolerability over time
The work reflects a strong interest in improving everyday functioning and long-term care for patients affected by severe psychiatric illness.
Nervous System Diseases and Mental Disorders in Alzheimer’s Disease
This research site is actively involved in studies of Alzheimer’s disease and its psychiatric complications, including agitation and psychosis. The trials aim to test new therapies that may help manage distressing behavioral symptoms and improve quality of life for patients and caregivers.
- Evaluating treatments for agitation in Alzheimer’s dementia
- Assessing therapies for psychosis associated with Alzheimer’s disease
- Measuring safety, tolerability, and symptom improvement
These studies address an important overlap between neurology and psychiatry, where behavioral symptoms can be especially challenging to treat.
Mental Disorders in Major Depressive Disorder and Bipolar-I Disorder
Clinical research at Psychiatrická ambulancia also includes mood disorders such as major depressive disorder and bipolar-I disorder. The trials are focused on improving depression symptoms, easing manic episodes, and understanding the long-term safety of new adjunctive or standalone treatment approaches.
- Studying new options for depression that are used alongside current antidepressants
- Evaluating treatments for mania and mania with mixed features in bipolar-I disorder
- Tracking long-term safety and tolerability in mood disorder care
Overall, the site contributes to research aimed at better symptom control and more durable treatment benefits for people with persistent mood disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Epamed s.r.o.
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of ITI-1284 in Psychosis Associated with Alzheimer's Disease: A Randomized, Double-Blind, Placebo-Controlled Study | Intra-Cellular Therapies Inc. | Phase II | Recruiting | Jul 2025 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Trospium Chloride | 4 | Unknown | 2024-05-09 | 2025-09-25 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.